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Summary 26 
Dermal and systemic infections caused by the Chrysosporium anamorph of Nannizziopsis 27 
vriesii (CANV) are highly prevalent in reptiles, resulting in severe disease and high mortality. 28 
Due to the high incidence of therapeutic failure, optimizing treatment is required. In this 29 
study, at first, the minimal inhibitory concentrations (MIC) of itraconazole, voriconazole, 30 
amphotericin B and terbinafine against thirty two CANV isolates were determined. For 31 
voriconazole, amphotericin B and terbinafine a monomodal MIC distribution was seen, 32 
whereas a bimodal MIC distribution was present for itraconazole, indicating acquired 33 
resistance in one isolate. Fourteen naturally infected bearded dragons (Pogona vitticeps), 34 
from the same owner, were treated orally either with itraconazole (5 mg/kg q24h) or 35 
voriconazole (10 mg/kg q24h). The clinical condition, drug plasma concentrations and the 36 
presence of CANV in skin samples were followed up. The animals were treated until 37 
complete clearance of the fungus. The plasma concentrations of voriconazole and 38 
itraconazole exceeded the minimal inhibitory concentration of the CANV isolate. Elimination 39 
of CANV was achieved in 27 and 47 days on average for itraconazole and voriconazole, 40 
respectively. Whereas only 2 out of 7 survived after itraconazole treatment, only a single 41 
animal died in the voriconazole treated group. In conclusion, based on a limited number of 42 
animals, voriconazole applied at a regimen of 10 mg/kg bodyweight (BW) q24h seems to be 43 
a safe and effective antimycotic drug to eliminate CANV infections in bearded dragons.   44 
 45 
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Introduction 51 
The Chrysosporium anamorph of Nannizziopsis vriesii (CANV) recently emerged as a cause 52 
of mycotic dermatitis in different reptile species such as bearded dragons (Pogona 53 
vitticeps)[1], chameleons (Chameleo spp.)[2], green iguanas (Iguana iguana)[3], ameiva 54 
lizard (Ameiva chaitzami)[4], salt-water crocodiles (Crocodylus porosus)[5] and snakes 55 
(Boiga irregularis; Erpeton tentaculatum)[6,7]. Very little is known about the source of this 56 
fungus, its prevalence in the environment and its virulence factors. Recent studies indicate 57 
that the CANV is not a common constituent of the mycobiota of the reptilian skin [8]. Koch’s 58 
postulates have been fulfilled in veiled chameleons (Chameleo calyptratus)[9]. 59 
Environmental stressors such as substandard husbandry and suboptimal cage temperatures 60 
may act as predisposing factors for CANV infections in reptiles [3].  61 
Successful treatment of reptiles infected with CANV has been achieved by administering 62 
itraconazole in a Parson’s chameleon (Chamaeleo parsonii) and in a bearded dragon [1,2]. 63 
Ketoconazole was effective in two green iguanas [3]. However, treatment with antimycotics 64 
was often unsuccessful [1,2]. To optimize the treatment outcome, antifungal drug selection, 65 
determination and administration of the optimal dose and frequency of antimycotic drugs are 66 
essential. In general, this requires integration of knowledge regarding the drug’s 67 
pharmacokinetic profile with its antimycotic properties [10]. 68 
The use of voriconazole, a novel triazole antifungal agent, has never been described for 69 
reptiles. However the in vitro activity of voriconazole against filamentous fungi exceeds that 70 
of itraconazole [11]. Azoles inhibit the P450-dependent 14-α-sterol demethylase by which 71 
exposed fungi become depleted of ergosterol and accumulate 14-α-methylated sterols. This 72 
leads to disruption of membrane function and structure, resulting in fungal growth inhibition 73 
[12].  74 
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The aim of this treatment study was to evaluate the in vitro activity of itraconazole, 75 
voriconazole, amphotericine B and terbinafine against different isolates of CANV and to 76 
compare the efficacy of itraconazole and voriconazole treatment of CANV infections in 77 
bearded dragons. In addition the plasma concentration of itraconazole and voriconazole in a 78 
group of naturally infected bearded dragons was monitored. 79 
 80 
Material and methods 81 
In vitro susceptibility testing 82 
Susceptibility testing was performed based on the guidelines of the Clinical and Laboratory 83 
Standards Institute (CLSI) document M38-A2. Thirty two isolates of CANV were tested. All 84 
of these isolates were obtained from clinically affected animals (3 green iguanas, 28 bearded 85 
dragons and 1 giant girdled lizard (Cordylus giganteus)).  86 
 87 
Antifungal agents 88 
Stock solutions of voriconazole (Pfizer Global Pharmaceuticals, Ixelles, Belgium), 89 
itraconazole (Janssen, Beerse, Belgium), amphotericin B (SPRL Bristol-Myers Squibb, 90 
Brussels, Belgium) and terbinafine hydrochlorid (Sigma-Aldrich, St Louis, USA) were 91 
prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, USA), diluted to 100 92 
times their final concentrations and stored at -70°C before use.  93 
On the day of the test, the stock solutions were diluted 1:50 in RPMI 1640 medium buffered 94 
to pH 7.0 with morpholinepropanesulfonic acid buffer (Invitrogen, Merelbeke, Belgium), and 95 
dispensed into 96 U-shaped well microdilution trays. Each well contained 0.1 ml of the 96 
appropriate drug solution (2 x final concentration) ranging from 0.0625-32 µg/ml (final 97 
concentration 0.0313-16 µg/ml) for voriconazole, itraconazole and amphotericin B and 98 
0.002-1 µg/ml (final concentration 0.001-0.5 µg/ml) for terbinafine. 99 
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Inoculum preparation of the Nannizziopsis vriesii isolates  100 
The Nannizziopsis vriesii isolates, grown on Sabouraud dextrose agar for three weeks at 101 
30°C, were washed with 5 ml of 1% Tween 20 in sterile phosphate buffered saline (PBS) to 102 
harvest conidia. The conidia were adjusted to a concentration of 4x106 conidia/ml in PBS by 103 
hemocytometer count. These stock conidial suspensions were diluted 1:50 in RPMI 1640 104 
medium buffered to pH 7.0 with morpholinepropanesulfonic acid buffer, and dispensed into 105 
96 U-shaped well microdilution trays. Each well contained 0.1 ml of the diluted conidial 106 
suspensions. 107 
 108 
Inoculum preparation of the quality control strain Candida krusei (ATCC 6258-IHEM 9560) 109 
The Candida species was grown on Sabouraud dextrose agar and incubated at 35°C for 24 110 
hours. Stock suspension was prepared in PBS, adjusted to match the turbidity of a Mc 111 
Farland 0.5 standard and further diluted 1:50 in the standard RPMI 1640 medium. The quality 112 
control strain was tested in the same manner as the Nannizziopsis vriesii isolates and included 113 
on the same test day.  114 
 115 
Susceptibility testing 116 
Each test plate contained four drug-free growth controls of standard RPMI-1640 medium 117 
without antifungal agent plus 1% DMSO and one not inoculated-drug-free control to ensure 118 
the medium’s sterility. The test plates were incubated at 30°C and evaluated after 48, 72, 96 119 
and 120 hours. Two persons read the test plates independently to minimize variation in the 120 
interpretation of MIC end points. 121 
 122 
MIC endpoints for C. krusei 123 
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The MIC endpoint for the azoles and terbinafine was defined as the lowest concentration that 124 
produced 80% inhibition compared with the growth in the control well, but for amphotericin 125 
B, the endpoint was defined as the lowest concentration with complete inhibition of growth 126 
[13]. 127 
 128 
MIC endpoints for Nannizziopsis vriesii isolates 129 
The MIC endpoint for the azoles and amphotericin B was defined as the lowest concentration 130 
that produced complete inhibition of growth or the first optically clear well, whereas the MIC 131 
endpoint for terbinafine was defined as the lowest concentration that produced 80% inhibition 132 
compared with the growth in the control well. 133 
 134 
Treatment study 135 
Animals 136 
In September 2008 one owner presented fourteen bearded dragons with dermatitis on the 137 
head, hind limbs and ventrum at the Faculty of Veterinary Medicine, Ghent University, 138 
Belgium. Pure and abundant cultures of CANV were obtained from each animal after 139 
microbiological sampling of the lesions. On histological examination of skin samples the 140 
presence of intra-lesional hyphae was confirmed by using the Perodic Acid Shiff reaction 141 
(PAS). Polymerase chain reaction (PCR) and sequencing of the ITS1-5.8S-ITS2 region were 142 
performed for species confirmation [14]. Through search of the GenBank database, 100 % 143 
homology was found with a sequence previously published for Nannizziopsis vriesii 144 
AJ131681.   145 
During the hospitalisation period the bearded dragons were housed individually. The 146 
temperature was maintained at 28°-30°C with a 12-hour photoperiod. The diet consisted of 147 
vegetables and insects and there was free access to fresh drinking water.    148 
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Treatment 149 
The severity of the dermal lesions was evaluated for each bearded dragon based on the size 150 
and macroscopic aspect. Based on this evaluation, the fourteen bearded dragons were divided 151 
in two treatment groups so that each treatment group consisted of two animals with a distinct 152 
dermatitis, three animals with moderate lesions and two animals with a severe dermatitis. 153 
One treatment group received itraconazole (Sporanox®, Janssen-Cilag, Berchem, Belgium) 154 
orally q24h at a dosage of 5 mg/kg bodyweight (BW) and the other one voriconazole 155 
(Vfend®, Pfizer, Ixelles, Belgium) orally q24h at a dosage of 10 mg/kg BW. During the 156 
antifungal therapy, the bearded dragons were weighed once every seven days, and 157 
consecutive mycological sampling after debridement of the dermal lesions was performed.  158 
Blood samples to determine the plasma concentrations of antifungal drugs, taken from the 159 
ventral coccygeal vein, were collected prior to the first administration of the antifungal drugs 160 
(Cmin) and 2h after administration (estimated Cmax) during the first three days of treatment. 161 
Thereafter blood samples were taken once weekly. Blood (1 ml) was collected into heparin 162 
coated tubes (Microvette®, Sarstedt, Nümbrecht, Germany) and centrifugated (2400g for 10 163 
min at room temperature) immediately after collection. Plasma concentrations of 164 
voriconazole and itraconazole were measured using a LCMS/MS method slightly modified to 165 
the one described by Egle et al. (2005)[15]. The HPLC system consisted of a Thermo 166 
Surveyor MS pump Plus and a column heater module, the mass spectrometer was a TSQ-167 
Quantum triple-quadrupole instrument equipped with an electrospray ionization source 168 
operating in the positive ion mode, both from Thermo Electron Corporation (Waltham, 169 
USA). A PLRP-S column (100Ǻ, 5 µm, and 150x4.6 mm) from Polymer Laboratories 170 
(Varian inc., Sint-Katelijne-Waver, Belgium) was used for chromatographic separation with 171 
hydroxy-itraconazole as internal standard for the voriconazole analysis and voriconazole as 172 
internal standard for the itraconazole analysis. 173 
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A serum biochemistry profile and hematological evaluation was also performed on the blood 174 
samples after 4 days of treatment. 175 
 176 
Necropsy 177 
Animals which died during treatment were subjected to a necropsy. Samples from the liver, 178 
lung and skin were taken for mycological and histological examination.   179 
 180 
Results 181 
In vitro susceptibility testing 182 
The results of the in vitro susceptibility testing of amphotericin B, itraconazole, voriconazole 183 
and terbinafine are summarized in table 1. For voriconazole, terbinafine and amphotericin B a 184 
monomodal MIC distribution was seen. However a bimodal MIC distribution was present for 185 
itraconazole, indicating acquired resistance in one isolate in the higher range of MICs.  186 
For all isolates recovered during the antimycotic treatment in the case control study, the MIC 187 
of voriconazole was < 0.0313 µg/ml and of itraconazole < 0.0313 µg/ml. 188 
The MICs of the quality control strain Candida krusei (ATCC 6258-IHEM 9560) were within 189 
the established reference MIC ranges for voriconazole, itraconazole and amphotericin B 190 
described by Barry et al., 2000 [13]. No reference range is available for terbinafine. 191 
 192 
Treatment study 193 
The effect on the mortality and the efficacy to eradicate the infection of the two treatments is 194 
presented in table 2. Five animals in the itraconazole treatment group died after 5, 20, 22, 36, 195 
54 days of treatment, respectively. In none of these animals the fungus could be isolated from 196 
the internal organs. CANV was isolated from the skin of the lizards that died after 5 and 22 197 
days of treatment. Neither gross nor histological lesions were observed in the liver and lungs. 198 
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For the skin samples, a chronic, multifocal, ulcerative dermatitis with intralesional hyphae 199 
was seen. One animal out of seven treated with voriconazole, died after 25 days of treatment. 200 
CANV was isolated from the liver and lungs of this animal. CANV infection was cleared in 201 
all 6 voriconazole treated animals that survived. 202 
The mean plasma concentrations of itraconazole and voriconazole are presented in figure 1 203 
and 2, respectively. An accumulation of itraconazole was seen in the plasma of all the 204 
animals. Prior to and following each administration of itraconazole, the established Cmin and 205 
estimated Cmax ranged from 527.0-7519.0 (mean = 3737.05 µg/l) and 155.9-7825.3 µg/l 206 
(mean = 3643.88 µg/l), respectively. Voriconazole plasma concentrations showed more 207 
interindividual variation than itraconazole plasma concentrations. Prior to and following each 208 
administration of voriconazole, the established Cmin and estimated Cmax ranged 209 
from ≥ 57.9-12704.1 (mean = 3421.8 µg/l) and ≥ 911.0-14372.1 µg/l (mean = 5738.0 µg/l), 210 
respectively.     211 
The serum biochemical values of each bearded dragon are presented in table 3. Significantly 212 
increased levels of aspartate aminotransferase (AST) were observed in 4 animals treated with 213 
itraconazole and three animals treated with voriconazole. This is suggestive of liver damage.  214 
 215 
Discussion 216 
Based on a limited number of animals, this study suggests voriconazole 10 mg/kg BW q24h 217 
to be a safe and effective treatment for CANV infections in bearded dragons. Despite the long 218 
duration to clear the fungal infection, only one animal, suffering a systemic infection, died 219 
during treatment with voriconazole. Since it is not possible to predict how long the therapy 220 
should be administered, a weekly mycological follow-up using a swab from the lesions is 221 
recommended. 222 
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In this study the plasma concentrations of voriconazole were followed up during 18 days. 223 
Until now no pharmacokinetic studies of voriconazole in reptiles have been described in the 224 
literature. The results show that, as in humans and birds [17,18], the interindividual 225 
variability of voriconazole plasma concentrations in bearded dragons is high. During the 226 
therapy, an increased elimination of voriconazole was seen. This may be due to the induction 227 
of liver enzymes. This induction is also seen in pigeons, mice, rats, dogs, and African grey 228 
parrots [12,19,20,21]. In rats and dogs a dose-related increase in hepatic cytochrome P450 229 
content in livers and an associated increase in relative liver weight was consistent with auto 230 
induction of voriconazole metabolization, thereby leading to a significant increase in 231 
clearance [20].  232 
Itraconazole was very adequate in eliminating the CANV infection. After an average of four 233 
weeks, the fungus could not be re-isolated from the lesions. However, only two animals out 234 
of seven survived the therapy. Based on the blood biochemistry, toxicity due to itraconazole 235 
administration was suggested. This however could not be demonstrated via histological 236 
examination of the liver and lungs. In humans a concentration of 17.1 mg/l itraconazole in 237 
blood plasma results in a high probability of toxicity [22].  Bowman et al. (2007)[1] reported 238 
mortality in bearded dragons after itraconazole administration, but, similar to this case, 239 
toxicity could not be proven. This author suggested pulse therapy for itraconazole in reptiles. 240 
However, Edgerton and Griffin (2009)[23] described a non-successful treatment of a CANV 241 
infection in a bearded dragon with pulse therapy of itraconazole. Treatment regimens with a 242 
lower dosage or a longer dosing interval with a potential reduction of the risk of itraconazole 243 
toxicity should be further investigated. 244 
 MIC values in Chrysosporium species for itraconazole have been reported by de Hoog et al. 245 
(2000)[24] and ranged from 0.12 µg/ml to 0.63 µg/ml. Paré et al. (2005)[25] reported low but 246 
not further specified MICs for amphotericin B, terbinafin, itra- and voriconazole in CANV 247 
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isolates. In our study one isolate out of thirty two showed acquired resistance to itraconazole. 248 
A large scale study should be performed in order to get a better knowledge of the percentage 249 
of resistant CANV strains, their resistance mechanisms and the origin of resistance.  250 
In conclusion, based on a limited number of animals, despite interindividual variable 251 
pharmacokinetic properties and possible induction of liver enzymes voriconazole seems to be 252 
a safe and effective antimycotic drug to treat CANV infections in bearded dragons at a dose 253 
of 10 mg/kg BW q24h.   254 
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Table 1: In vitro activity of selected antifungal agents against 32 isolates of the 346 
Chrysosporium anamorph of Nannizziopsis vriesii from captive lizards.  347 
                                    MIC (µg/ml) 
 Antifungal agent  Range  50%  90% 
        
 Amphotericin B   0.0313-16 2  2 
 Itraconazole  0.0313-16  0.0313  0.25 
 Voriconazole  0.0313-16  0.0313  0.0625 
 Terbinafine  0.001-0.5 1  2 
 348 
        MIC=Minimal Inhibitory Concentration 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
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Table 2: Overview of the treatment duration, clearance of the infection and mortality in 367 
bearded dragons naturally infected with CANV after treatment with itraconazole or 368 
voriconazole.  369 
BW=BodyWeight 370 
 371 
 372 
 
Treatment duration (days) 
Range           Average 
Clearance of 
CANV infection 
Outcome of 
treatment 
Itraconazole 
(5 mg/kg BW q 24h) 
14-42                27 5/7 2/7 survived 
Voriconazole 
(10 mg/kg BW q24h) 
28-64                47 6/7 6/7 survived 
 17 
Table 3: Serum biochemical profile of the bearded dragons during the treatment. 373 
Treatment  Itraconazole Voriconazole 
 Reference valuea Average    (Range) Average    (Range) 
AST (IU/l)b 27± 23 192,7     (15 – 431) 157,4      (24 – 446) 
UA (mg/dl)b 4,4 ± 2,6 2,4      (0,9 - 3,5) 2,8        (0,9 - 5,2) 
Glu (mg/dl)b 201 ± 52 186,2     (148 – 251) 228,8       (191 – 282) 
Ca (mg/dl)b 16,2 ± 11,2 8,6     (5,1 – 14) 9,5          (7,9 - 10,9) 
Phos 
(mg/dl)b 5,6 ± 2,5 6,5      (5,9 - 7,6) 7,9          (5,2 - 10,1) 
TP (g/dl)b 5,0 ± 1,4 4,4      (3,7 - 5,3) 5,2         (4,4 - 6,7) 
Alb (g/dl)b 2,6 ± 0,8 1,86     (1,5 - 2,4) 2,3         (1,5 - 2,7) 
Glob (g/dl)b 2,3 ± 0,9 2,57     (2,2 - 3,2) 2,96       (2,4 – 4) 
K+ (mEq/l)b 3,8 ± 1,2 5,6      (3,4 - 7,4) 4,8         (1 - 9,2) 
Na+ 
(mEq/l)b 156 ± 11 168,4      (164 – 172) 170,7      (167 – 180) 
aReference value according to Pollock et al.[16]. 374 
bAST: aspartate aminotransferase, UA: uric acid, GLU: glucose, Ca: calcium, Phos: 375 
phosphorus, TP: total protein, ALB: albumin, GLOB: globulin, K+: potassium, Na+: sodiu376 
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Figure 1: Average (± SD) plasma concentration of itraconazole (µg/l) in bearded dragons 379 
(n=6) after oral administration of itraconazole at a dose of 5 mg/kg SID. 380 
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 389 
Figure 2: Average (± SD) plasma concentration (µg/l) of voriconazole in bearded dragons 390 
(n=7) after oral administration of voriconazole at a dose of 10 mg/kg SID 391 
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